Global Omeprazole
Market, by Dosage Form (Capsule, Powder, and Tablet), by Indication
(Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive
Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$
2,668.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over the
forecast period (2018 – 2026).
Launch of cost-effective generics
by the market players to augment the market growth The global omeprazole market
is expected to witness significant growth over the forecast period attributed
to increasing incidence of gastric ulcers caused due to H.pylori infection and
Nonsteroidal Anti-Inflammatory Drugs (NSAID) use. According to the study by
Deccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70%
of gastric ulcers are attributed due to Helicobacter pylori. Furthermore, the
study also stated that around 14-25% of gastric and duodenal ulcers are
associated with NSAID use. Furthermore, developers are focusing on approval and
launch of cost-effective generic versions of omeprazole in order to enhance
market sales. For instance, in July, 2017, Breckenridge Pharmaceutical, Inc.
received the U.S. Food and Drug Administration (FDA) approval of abbreviated
new drug application (ANDA) for Omeprazole delayed-release capsules. The drug
will be manufactured and supplied by parent company- Laboratorios Dr. Esteve,
S.A., Spain.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2380
Browse 22 Market Data Tables and
24 Figures spread through 138 Pages and in-depth TOC on “Omeprazole Market”-
Global Forecast to 2026, by Dosage Form (Capsule, Powder, and Tablet), by Indication
(Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive
Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa)
Gastroesophageal reflux disease
(GERD) is a chronic digestive disorder where the stomach acid enters esophagus,
causing inflammation. The condition results in a long-lasting and serious from
of acid reflux. According to the National Institute of Diabetes and Digestive
and Kidney Diseases, 2014, an estimated 15.1 to 30 percent of the U.S.
population is diagnosed with GERD. Moreover, According to the Department of
Gastroenterology, Cedars-Sinai Medical Center, 2014, over nine million primary
care visits in the U.S. are attributed to GERD annually, making it the most
common gastroenterology-related outpatient diagnosis disease in the country.
The market players are focused on developing treatment to offer heartburn
relief by implementing innovative technologies. For instance, in April, 2018,
Perrigo Company plc. and Dexcel Pharma Technologies, Ltd., launched Omeprazole
delayed release orally disintegrating tablets (ODT) 20mg, with innovative
MelTech melt-in-your-mouth technology for treating frequent heartburn. The
innovative technology provides an affordable option in the OTC category.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380
Key Takeaways of the Omeprazole
Market:
The global omeprazole market is
expected to exhibit a CAGR of 5.2% over the forecast period, owing to
increasing prevalence of peptic ulcer and acid related diseases and approval of
generic versions by regulatory agencies. For instance, in 2016, Perrigo Company
plc.received the U.S. FDA approval for omeprazole, thus launching a brand
equivalent to Zegerid OTC capsules. Zegerid OTC is indicated for the treatment
of frequent heartburn.
Among distribution channel, the
online pharmacy segment is expected to holds a dominant position in the
omeprazole market in 2026, owing to the higher amount of discount coupons
granted for the generic and OTC omeprazole drugs
Some of the major players
operating in the global omeprazole market include, Astrazeneca Plc., Sandoz,
Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax
Laboratories, Inc., Perrigo Company Plc., Santarus, Inc., Watson laboratories,
Inc., and Lek Pharmaceuticals d.d.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2380
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
